Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01535183 : Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
PhasePhase 2
AgesMin: N/A Max: 19 Years
Eligibility
Inclusion Criteria:

- Diagnosis of brain tumor : embryonal brain tumor (medulloblastoma, CNS PNET, ATRT,
etc), intracranial germ cell tumor

- Relapse or refractory state

- Prior therapy : Patients must have fully recovered from the acute toxic effects of
all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
Patients are eligible 8 weeks from the day of stem cell infusion for autologous stem
cell transplant, if hematological and all other eligibility criteria are met.

- Performance status: ECOG 0-2.

- Patients must be free of significant functional deficits in major organs, but the
following eligibility criteria may be modified in individual cases.

1. Heart: a shortening fraction ? 28%

2. Liver: total bilirubin < 2 × upper limit of normal; ALT < 3 × upper limit of
normal.

3. Kidney: creatinine <2 × normal

- Patients must lack any active viral infections or active fungal infection.

- Patients (or one of parents if patients age < 20) should sign informed consent.

Exclusion Criteria:

- Pregnant or nursing women.

- Malignant (except brain tumor) or nonmalignant illness that is uncontrolled or whose
control may be jeopardized by complications of study therapy.

- Psychiatric disorder that would preclude compliance.

- Patients who, in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01535183      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740